These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 39112571)

  • 1. Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.
    Suzuki Y; Kaneko H; Nagasawa H; Okada A; Fujiu K; Jo T; Takeda N; Morita H; Nishiyama A; Gohda T; Suzuki Y; Node K; Yasunaga H; Nangaku M; Komuro I
    Diabetes Obes Metab; 2024 Jun; 26(6):2422-2430. PubMed ID: 38528820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Kintzoglanakis K; Diamantis C; Mariolis A; Paschou SA
    Diab Vasc Dis Res; 2024; 21(4):14791641241269743. PubMed ID: 39139128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors.
    Liu J; Su X; Hao Y; Liu J;
    Sci Rep; 2024 Aug; 14(1):18290. PubMed ID: 39112571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
    Anson M; Henney AE; Zhao SS; Ibarburu GH; Lip GYH; Cuthbertson DJ; Nabrdalik K; Alam U
    Diabetes Obes Metab; 2024 Jul; 26(7):2606-2623. PubMed ID: 38558280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
    ; Tsukamoto S; Kobayashi K; Toyoda M; Tone A; Kawanami D; Suzuki D; Tsuriya D; Machimura H; Shimura H; Wakui H; Takeda H; Yokomizo H; Takeshita K; Chin K; Kanasaki K; Miyauchi M; Saburi M; Morita M; Yomota M; Kimura M; Hatori N; Nakajima S; Ito S; Murata T; Matsushita T; Furuki T; Hashimoto T; Umezono T; Muta Y; Takashi Y; Tamura K
    Diabetes Obes Metab; 2024 Aug; 26(8):3248-3260. PubMed ID: 38764356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-An expert consensus statement.
    Liew A; Lydia A; Matawaran BJ; Susantitaphong P; Tran HTB; Lim LL
    Nephrology (Carlton); 2023 Aug; 28(8):415-424. PubMed ID: 37153973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ; Aroda VR; Collins BS; Gabbay RA; Green J; Maruthur NM; Rosas SE; Del Prato S; Mathieu C; Mingrone G; Rossing P; Tankova T; Tsapas A; Buse JB
    Diabetologia; 2022 Dec; 65(12):1925-1966. PubMed ID: 36151309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
    Mahtta D; Ramsey DJ; Lee MT; Chen L; Al Rifai M; Akeroyd JM; Vaughan EM; Matheny ME; Santo KRDE; Navaneethan SD; Lavie CJ; Birnbaum Y; Ballantyne CM; Petersen LA; Virani SS
    Diabetes Care; 2022 Feb; 45(2):372-380. PubMed ID: 35015080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.
    Mosenzon O; Alguwaihes A; Leon JLA; Bayram F; Darmon P; Davis TME; Dieuzeide G; Eriksen KT; Hong T; Kaltoft MS; Lengyel C; Rhee NA; Russo GT; Shirabe S; Urbancova K; Vencio S;
    Cardiovasc Diabetol; 2021 Jul; 20(1):154. PubMed ID: 34315481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study.
    Li Y; Teng D; Shi X; Qin G; Qin Y; Quan H; Shi B; Sun H; Ba J; Chen B; Du J; He L; Lai X; Li Y; Chi H; Liao E; Liu C; Liu L; Tang X; Tong N; Wang G; Zhang JA; Wang Y; Xue Y; Yan L; Yang J; Yang L; Yao Y; Ye Z; Zhang Q; Zhang L; Zhu J; Zhu M; Ning G; Mu Y; Zhao J; Teng W; Shan Z
    BMJ; 2020 Apr; 369():m997. PubMed ID: 32345662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 9. Pharmacologic Approaches to Glycemic Treatment:
    American Diabetes Association
    Diabetes Care; 2020 Jan; 43(Suppl 1):S98-S110. PubMed ID: 31862752
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.